To assess the PK and safety profiles of ARQ 197 in extensive and poor metabolizers, as defined by CYP 2C19 genotype
This is a pharmacokinetic study designed to compare the metabolism of ARQ 197 in normal healthy volunteers who are extensive metabolizers (EM) or poor metabolizers (PM) as defined by CYP 2C19 genotype. This is an open-label, single-dose, parallel group design in which healthy volunteer subjects will receive a single dose of ARQ 197
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
17
Treatment with ARQ 197
Covance Clinical Research Unit, Inc.
Evansville, Indiana, United States
To assess the PK and safety profiles of ARQ 197 in extensive and poor metabolizers, as defined by CYP 2C19 genotype
Time frame: May 2008
To assess the effect of other CYP genotypes on the safety profile and PK profile of ARQ 197
Time frame: May 2008
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.